NCT07894341
A Clinical Study of Long-Term Administration of Inpegsomatropin Injection in Participants With Idiopathic Short Stature Who Have Completed Phase Ⅲ Clinical Trials
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Safety: number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results.
Timeframe: Every 13 weeks during the first year, and then every 52 weeks (up to 16 years)
Secondary (6)
Change in height standard deviation score (ΔHT-SDS)
Height velocity (HV)
Change in height velocity (ΔHV)
Change in insulin-like growth factor-1 standard deviation score (ΔIGF-1-SDS)
Ratio of change in bone age to change in chronological age (ΔBA/ΔCA)
Show 1 moreShow less
Final height (FH)
Arms and interventions
Inpegsomatropin-Injection GroupExperimental
Drugs: Inpegsomatropin Injection
Sites
27 sites in 1 country